Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Clinial Trials

Celgene building

Celgene hopes for second time lucky for ozanimod FDA filing

One of six key drugs for BMS-Celgene merger

- PMLiVE

Setback for Vertex’s cystic fibrosis challenger Proteostasis

Unlikely to match market leader's triple therapy

- PMLiVE

Aimmune preps EU filing for peanut allergy immunotherapy

Company set to be first to market

- PMLiVE

Bluebird plays down report of EU gene therapy approval

Charity says Zynteglo (LentiGlobin) has already achieved a conditional marketing authorisation

- PMLiVE

DDB Remedy, Cuttsy + Cuttsy and Cello win agency workplace awards

Havas London and Wordbird also among winners

- PMLiVE

Janssen looks to expand Darzalex in Europe

Regimen reduced risk of disease progression or death by 44%

- PMLiVE

Success for AZ, setback for Sanofi in type 1 diabetes

Forxiga approved as add-on to insulin

- PMLiVE

Otsuka’s Alzheimer’s agitation drug hits the mark

Drug addresses one of the most challenging symptoms in dementia care

Hidden health system costs: false positives and negatives

Decision theory sheds light on the things we don’t often pay attention to in healthcare

- PMLiVE

Investments show UK biotech still booming despite Brexit

UK raised a quarter of all European biotech funds

- PMLiVE

Fishawack acquires Dudnyk

Agency to boost abilities in rare diseases and oncology

- PMLiVE

GSK’s myeloma drug hits target, prompting rapid filing pledge

Antibody drug conjugate could challenge CAR-Ts

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links